 |
|
|
| |
DUAL ORAL THERAPY WITH THE NS5A INHIBITOR DACLATASVIR (BMS-790052) AND THE NS3 PROTEASE INHIBITOR ASUNAPREVIR (BMS-650032) IN HCV GENOTYPE 1b-INFECTED NULL RESPONDERS OR PATIENTS INELIGIBLE/INTOLERANT TO PEGINTERFERON/RIBAVIRIN
|
| |
| |
Reported by Jules Levin
22nd Conference of the Asian Pacific Association for the Study of the Liver (APASL 2012), Taipei International Convention Center, February 16-19, 2012
KARINO Y,1 TOYOTA J,1 OHMURA T,1 IKEDA K,2 SUZUKI Y,2 CHAYAMA K,3 TAKAHASHI S,3 KAWAKAMI Y,3 KUMADA H2
1SAPPORO KOSEI GENERAL HOSPITAL, SAPPORO, JAPAN; 2TORANOMON HOSPITAL, TOKYO, JAPAN; 3HIROSHIMA UNIVERSITY, HIROSHIMA, JAPAN
|
| |
|
|
|
|
|
